Anti-Human CD20 (Obinutuzumab Biosimilar)
Catalog #500043
| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 500043 | 1 mg | $200.00 | ||
| 500043 | 5 mg | $600.00 | ||
| 500043 | 20 mg | $1,250.00 |
Product Details
Obinutuzumab is a recombinant humanized monoclonal antibody (IgG1) that specifically targets the CD20 antigen on B cells. As a biosimilar to the FDA-approved therapeutic obinutuzumab, it is designed to enhance B-cell depletion through multiple mechanisms, including direct cytotoxicity, antibody-dependent cellular cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC). Obinutuzumab binds to the CD20 antigen expressed on mature B cells, triggering immune-mediated cytotoxic mechanisms. This leads to B-cell apoptosis and depletion, making it an effective tool for research in B-cell malignancies and autoimmune diseases.
Specifications
| Clone | Obinutuzumab |
|---|---|
| Reactivities | Human |
| Isotype | Human IgG1 |
| Recommended Isotype Control | Human IgG1 isotype control |
| Format | Liquid |
| Formluation | PBS, pH 6.0 |
| Sterility | 0.2 µm filtered |
| Clonality | Recombinant |
| Conjugation | Unconjugated |
| Immunogen | Human CD20 |
| Host | CHO cells |
| Purity | >95% (HPLC, SDS-PAGE) |
| Endotoxin | < 1.0 EU/mg (LAL assay) |
| Grade | In vivo ready (RUO) |
| Application | Neutralization; Flow Cytometry; ELISA; WB |
| Purification | Protein A |
| Storage Conditions | 2-8 °C, Avoid freeze / thaw cycle |
| Shelf Life | 6 months |
| Regulatory Status | RUO |